Cryo Precitipitate

PreclinicalBiologic

IInstitute of Liver and Biliary Sciences, India

Cryo Precitipitate is one of 3 biologic programs targeting Coagulopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CoagulopathyCompleted

CoagulopathyPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Coagulopathy

#DrugCompanyPhaseTrials

Fresh Frozen Plasma

CSL Behring

Preclinical

3 2

Fibrinogen Concentrate

GGold Coast Hospital and Health Service

Preclinical

1 3

Cryo Precitipitate

IInstitute of Liver and Biliary Sciences, India

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Coagulopathy1 trial

TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02689232·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cryo Precitipitate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cryo Precitipitate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cryo Precitipitate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Liver and Biliary Sciences, India

Cryo Precitipitate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Coagulopathy1 trial

References

Drug Info

Quick Facts

Related News